Uptake Medical is focused on the development and commercialization of innovative, non-surgical treatments for lung diseases. InterVapor is the first and only approach to endoscopic lung volume reduction for people with severe emphysema that uses the body's natural healing process without leaving any implants or foreign materials in the lung. In clinical studies, InterVapor has demonstrated clinically meaningful improvements in breathing function, exercise capacity and quality of life. With headquarters in Tustin, Calif., Uptake Medical received the CE mark and TGA approval to commercialize InterVapor.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/09/12 | undisclosed | Series C |
Affinity Capital Crescent Point Group GBS Venture Partners Maverick Capital WRF Capital | undisclosed |
